David T. Durack, MD, D Phil, FRCP, FRACP, FACP


Dr. David T. Durack is Consulting Professor of Medicine at Duke University and was previously Senior Vice President, Corporate Medical Affairs and Chief Medical Officer at Becton Dickinson & Co.

Dr. Durack has broad and deep expertise in the area of infectious diseases. He has performed extensive research on the pathogenesis and chemotherapy of bacterial and fungal infections, authoring his doctoral thesis entitled “Experimental Endocarditis” at Oxford University.

Earlier in his clinical career, Dr. Durack was Chief Resident and faculty member in the Department of Medicine at the University of Washington, eventually becoming Chief of the Division of Infectious Diseases and International Health. Following his time at University of Washington, Dr. Durack was Professor of Medicine at Duke University. In addition to his clinical work, Dr. Durack has published more than 230 articles and textbook chapters and co-edited several textbooks.

Dr. Durack is a Fellow of the Royal College of Physicians (UK), the Royal Australasian College of Physicians, and the American College of Physicians. He has been elected to the American Society for Clinical Investigation, the Council of the Infectious Diseases Society of America, and the American Academy of Microbiology. He has served on an FDA Review Panel, the Joint Commission Resources Board of Directors, and as Chairman of the Board, ASM Resources. He is currently a Director for PixelEXX Systems Inc. and has 17 years’ experience as a Medical Affairs functional leader and executive officer in the medical devices and diagnostics industry.

Dr. Durack attended the Correspondence School of West Australia and Scotch College. He earned his medical degree from University of Western Australia and went on to Oxford University as a Rhodes Scholar where he completed his Doctor of Philosophy. Dr. Durack’s internship and residencies were conducted at Radcliffe Infirmary in Oxford and Royal Postgraduate Medical School at Hammersmith Hospital in London.

Franklin R. Cockerill, III, M.D.

Dr. Frank Cockerill currently is the CEO of Analyte Health located in Chicago, Illinois. Analyte Health is a leading digital laboratory testing company providing online laboratory services for sexually transmitted diseases.

Dr. Cockerill is the immediate past Chair of Department of Laboratory Medicine and Pathology, Mayo Clinic, and President and CEO of Mayo Collaborative Services, Inc. (MCSI)/Mayo Medical Laboratories (MML). While at Mayo he also carried a named professorship, the Ann and Leo Markin Professor of Medicine and Microbiology at the Mayo Medical School.

Dr. Cockerill is Board Certified in Internal Medicine and Infectious Diseases (American Board of Internal Medicine) and Clinical Microbiology (American Board of Pathology). He practiced Internal Medicine and Infectious Diseases for over a decade before shifting his focus to Clinical Microbiology. Dr. Cockerill’s research interests have ranged from basic discovery to applied science with a special emphasis on the phenotypic and genotypic identification of antimicrobial resistance.

Dr. Cockerill has authored or co-authored over 150 publications in the medical literature many of which relate to diagnostic testing for infectious diseases. He and his research team at Mayo developed numerous real-time PCR assays, which have significant advantages over conventional culture-based assays, and include the first commercially available rapid PCR test for Anthrax. This work has resulted in 8 US patents, 2 foreign patents and 56 licensed technologies.

As President and CEO of Mayo Collaborative Services, Inc. (MCSI), Dr. Cockerill oversaw the largest for-profit company associated with Mayo Clinic. The major service line of MCSI, Mayo Medical Laboratories (MML), is the third largest provider of esoteric laboratory services in the United States and, in total, serves over 4000 clients in 130 countries.

Dr. Cockerill’s current or recent extramural leadership positions include Chair of the Subcommittee on Antimicrobial Susceptibility Testing, Clinical Laboratory Standards Institute (CLSI), Chair, Microbiology Devices Panel of the Medical Devices Advisory Committee of the US Food and Drug Administration (FDA), Board Member and Program Director, of the Association for Molecular Pathology (AMP), Director, American Clinical Laboratory Association Board; Director, Board of Scientific Counselors of the Centers for Disease Control and Prevention (CDC) and Editor, Journal of Clinical Microbiology.

Finally, Dr. Cockerill has received numerous awards, fellowships and honors including the BD Award for Research in Clinical Microbiology, the Laboratory Public Service National Leadership Award and Fellowship in the American Academy of Microbiology. The BD Award, sponsored by the American Society for Microbiology (ASM), is the highest honor bestowed upon a clinical microbiologist in the United States. The Laboratory Public Service National Leadership recognizes significant contributions to the healthcare of the American public with past recipients including both scientists and US senators and congressmen.


Lance R. Peterson, MD, FASCP, FIDSA, FAAM, FSHEA, is the Director of Microbiology and Infectious Diseases Research, vice-Chair of Pathology for Research, and Epidemiologist at NorthShore University HealthSystem, in Evanston, Illinois. He is also a Clinical Professor at the Pritzker School of Medicine of the University of Chicago, in Chicago, Illinois, and a staff member in the Clinical Microbiology and Infectious Disease Divisions at Evanston Hospital. Dr. Peterson received he MD degree from the University of Minnesota and is certified in Internal Medicine, Infectious Diseases and Medical Microbiology

His research interests have included the study of infections in the extremities of diabetic patients; investigations of antimicrobial agents in models that simulate closed space, neutropenic infections; the epidemiology of nosocomial pathogens (particularly MRSA, enterococci, MDR Gram negative bacteria, and Clostridium difficile); the development and evaluation of molecular diagnostic testing; measuring activity of new antimicrobial compounds against bacteria and fungi; and the study of the molecular mechanisms for the resistance of staphylococci and pneumococci to the new fluoroquinolone antimicrobial agents. Current research activities focus on using molecular testing methods to enhance infection control activities; understanding the regulation of antimicrobial agent resistance in staphylococci and Enterobacteriaceae; designing novel strategies for treatment of infections due to resistant bacteria; testing innovations to reduce catheter-related blood stream infections; and developing new diagnostic tests for rapidly detecting antibiotic resistant bacterial pathogens. He has over 700 scientific publications/presentations and is recognized in the 21st Century editions of Marquis’ Who’s Who.

William J. McDaniel, M.D., Rear Admiral, U.S. Navy (ret)

Dr. McDaniel was born on a farm near Muskogee, Oklahoma and attended college on a full wrestling scholarship at Oklahoma State University where he received a Bachelor of Science degree in Physiology. Following graduation, he began studies at the University of Oklahoma School of Medicine and received his Doctor of Medicine degree in 1968. He completed his internship at St. Francis Hospital in Tulsa, Oklahoma in 1969.

After commissioning in the Navy in 1969, Dr. McDaniel served in a variety of locations, including Viet Nam, Spain, Japan, Korea, and Hawaii over the course of 30 years. He had a total of five commands, assuming command of Naval Hospital, Charleston, South Carolina, in 1988, which became a key medical facility during Hurricane Hugo in 1989. He was selected as Rear Admiral in 1989. In June, 1990, he became the Surgeon for the U.S. Pacific Command, Camp H.M. Smith, Hawaii. In 1992 he assumed command of the Naval Medical Center, Portsmouth, Virginia, and received his second star there in 1993.

Since retiring from the navy in January, 1997, Dr. McDaniel has worked as a consultant or board member for multiple organizations, including Imatron, Inc.; Center for Naval Analysis; Chairman of a Flag/General Advisory Board to the Applied Physics Laboratory, Johns Hopkins University; and, as a consultant to the Under Secretary of Defense for Personnel and Readiness, the Honorable Rudy de Leon. He served on the U.S. Olympic Committee as the co-chairman for the Sports Medicine 2000 committee from 1997-2000, and was the physician for the U.S. Freestyle Wrestling team in the World Championships in Ankara, Turkey, in 1999, and for the World Cup Freestyle Championships in 2000. He was the Chairman of a Blue Ribbon Panel formed by the CNO for the assessment of the future of National Naval Medical Center, Bethesda, MD, in 2000.

Following the tragedy of 9/11, he became the federal liaison for Johns Hopkins University in preparing their Homeland Security plan. He was a consultant for EADS North America on development of field medical hospitals, and was a part time consultant for EAI Corporation and for Northrup Grumman. He was on the Board of Advisors for Aetna Insurance Company of Hartford, CT, from 2007-2010. He is currently a Board member for Computer Technology Associates, on the Board of Advisors of Haven Behavioral Healthcare, Inc., and on the Board of Directors for Vioguard, Inc., of Seattle, WA. He is Chairman of the Board for DEEC (Diesel Engine Emission Control) of Bellevue, Wa.

Dr. McDaniel was hired by the Commander-in-Chief of the Pacific Fleet in Hawaii to head the advance team into Banda Aceh following the tsunami of December, 2004, preceding USNS Mercy’s arrival. He spent 2 months in Banda Aceh working on issues of public health, then spent almost another month working on Nias Island, Indonesia, following the earthquake there. He has been an extremely active lecturer around the nation about this activity, strongly supporting a movement to continue using military medical assets for medical assist visits around the world. He has given multiple lectures on leadership around the US. He has authored a book about that experience, “Faces of the Tsunami,” which is currently in the process of publication.

Daniel J. Sexton, M.D.

Dr. Sexton is a graduate of the Northwestern University School of Medicine and is currently a Professor of Medicine at the Duke University School of Medicine.

Early in his career, Dr. Secton spent two years as an Epidemic Intelligence Service Officer at the CDC. In addition to 11 years of experience in private practice in Oklahoma City, Dr. Sexton also worked at Monash Medical Center in Melbourne Australia while on sabbatical in 1989. He was made an honorary lifetime member of the Australasian Society for Infectious Diseases in 2006.

Dr. Sexton has had a direct role in the training of numerous medical students, residents, fellows and post-doctoral students during the 26 years he has been on the Duke faculty. Fourteen of 20 fellows who worked under Dr. Sexton’s supervision are currently hospital epidemiologists and active in research related to HAIs.

Dr. Sexton is one of five Editors in Chief of the Infectious Disease section of UpToDate. He has published more than 200 peer reviewed original manuscripts. He is a recipient of the Clinician Award from the Infectious Diseases Society of America and was previously the Chair of the IDSA Clinical Affairs Committee and served on the IDSA Board of Directors and the Board of the National Foundation for Infectious Diseases.

Dr. Secton has received the Golden Apple Teaching Award from the Duke University School of Medicine, a Golden Apple Award from the American Medical School Student Association, The Eugene Stead Award for Excellence in Teaching from the Duke Medicine Housestaff (twice) and was named a Master Clinician Teacher by the Duke University School of Medicine in 2011.

Dr. Sexton’s multiple research interests include the risk factors, outcomes and definition of healthcare-associated bloodstream and surgical site infections, risk factors and outcomes of infections due to Staphylococcus aureus and criteria, outcomes and complications of infective endocarditis. He founded the Duke Infection Control Outreach Network in 1997 that has since grown to include 43 community hospitals in 6 states. Dr. Sexton is currently the principal investigator on one of 5 epicenter grants awarded by the Centers for Disease Control, and the PI for grants from The Duke Foundation and the CDC Foundation related to the Duke Antimicrobial Stewardship Outreach network which he founded in 2013.